Pharma Investments, Ventures & Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Investments, Ventures & Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Acute Lymphoblastic Leukemia
Findings from University of Texas broaden understanding of acute lymphoblastic leukemia
April 6th, 2008
According to recent research from the United States, "To identify factors associated with relapse-free survival (RFS), 80 patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia, enrolled in a phase 11 study of imatinib-combined chemotherapy, were analyzed. The median follow-up of surviving patients was 26.7 months (maximum, 52.5 months)." "Twenty-eight out of 77 patients who had achieved CR relapsed. The probability of RFS was 50.5% at 2 years," wrote M. Yanada and colleagues, University of Texas. The researchers concluded: "Multivariate analysis revealed that the presence of secondary chromosome aberrations in...
Source: Pharma Investments, Ventures & Law Weekly (2008-04-06)
|
